Fig. 5

bMSC derived EVs delivered miR let-7-5p targets endothelial ABL2. A Highly enrichment gene ontology pathways for target genes of co-expressed miRNAs in bMSC-EVs. red label: terms of high targeting ratio, p < 0.001. B Dual-luciferase report of let-7-5p and the ABL2 gene: luciferase activity of wild-type ABL2 gene and the ABL2 gene with the 3′-UTR binding sequence of let-7a-5p, let-7b-5p, let-7i-5p sequence MUT. C Western blot images and quantitative analysis of the ABL2 level treated with normal bMSCs and let-7-deficient bMSCs compared to that of Actin in mice right ear tissues, (n = 6). D Immunohistochemistry images of ABL2 expression with the treatment as described in (B). Red arrow: ABL2 staining on ear vascular endothelium, Scale bar: 20 μm (n = 6). E Western blot images and quantitative analysis of ABL2 protein and gene expression in human umbilical vein endothelial cells (HUVECs) treated with normal bMSC med and bMSC-let-7(−) med compared with that of Actin and gapdh respectively (n = 3). For B, C, D, and E results were obtained at 6 h after LPS administration. Values are presented as mean ± sems; statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001